24/7 Market News Snapshot 08 October, 2025 – bioAffinity Technologies, Inc. Common Stock (NASDAQ:BIAF)
DENVER, Colo., 08 October, 2025 (www.247marketnews.com) – (NASDAQ:BIAF) are discussed in this article.
BioAffinity Technologies, Inc. has announced a notable advancement in its financial strategies through a registered direct offering aimed at furthering its mission in cancer diagnostics. The company will sell 720,000 shares of common stock at a price of $2.50 per share, which is expected to generate approximately $1.8 million in gross proceeds. This move aligns with the company’s ongoing ambition to bolster its market presence and support the continued development of its flagship product, CyPath® Lung, a pioneering noninvasive test for early-stage lung cancer.
The closing of this offering, anticipated around October 9, 2025, hinges on standard closing conditions. The net proceeds will be strategically utilized to enhance working capital and expand sales efforts for CyPath® Lung, reinforcing BioAffinity’s commitment to addressing the pressing need for efficient cancer diagnostics. The test boasts impressive sensitivity and specificity for early detection of lung cancer, positioning it as a valuable tool in combating this widespread health challenge. Currently, CyPath® Lung is marketed through Precision Pathology Laboratory Services, a subsidiary of BioAffinity Technologies.
The company recently experienced a noteworthy stock surge, with shares opening at $3.14 and peaking with a remarkable increase of 22.61%, reflecting strong investor interest and robust trading activity. Currently, the stock trades at $3.004, supported by a significant trading volume of nearly 35 million shares. BioAffinity Technologies remains dedicated to innovation in cancer detection, actively working to elevate health outcomes while ensuring regulatory compliance and transparency in its financial undertakings. This concerted focus on growth and technological advancement signals a promising trajectory for the company as it navigates the evolving landscape of biotechnology.